Personal Genomics Taiwan Inc v. Pacific Biosciences Of California Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Personal Genomics Taiwan, Inc. (Taiwan)
  • Defendant: Pacific Biosciences of California, Inc. (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 5:24-cv-04098, D. Del., 09/26/2019
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because the Defendant, Pacific Biosciences of California, Inc., is a Delaware corporation and therefore "resides" in the district.
• Core Dispute: Plaintiff alleges that Defendant's Sequel and Sequel II gene sequencing systems infringe a patent related to single-molecule detection apparatuses.
• Technical Context: The technology concerns apparatuses for single-molecule bioassays, a key component in next-generation DNA sequencing aimed at reducing cost and complexity by enabling massively parallel detection.
• Key Procedural History: The complaint alleges a history of licensing discussions between the parties and/or their predecessors from 2010 to 2015, and alleges Defendant cited the patent-in-suit during its own patent prosecution. Subsequent to the filing of the complaint, U.S. Patent No. 7,767,441 was the subject of Inter Partes Review proceedings (IPR2020-01163; IPR2020-01200), which resulted in the cancellation of several claims, including representative apparatus claim 48 asserted in the complaint.

Case Timeline

Date	Event
2007-10-25	Priority date for U.S. Patent No. 7,767,441
2010-03-03	Defendant PacBio allegedly contacted Plaintiff's predecessor (ITRI) about the technology
2010-08-03	U.S. Patent No. 7,767,441 issued
2015-09-30	Accused Product "Sequel System" launched
2019-04-24	Accused Product "Sequel II System" launched
2019-06-10	'441 Patent assigned to Plaintiff PGI
2019-09-26	Complaint filed
2020-06-22	IPR2020-01163 filed against '441 Patent
2020-06-27	IPR2020-01200 filed against '441 Patent
2024-05-08	Inter Partes Review Certificate issued, cancelling claims including asserted claim 48

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,767,441 - "Bioassay system including optical detection apparatuses, and method for detecting biomolecules"

The Invention Explained

• Problem Addressed: The patent's background section describes conventional high-throughput DNA sequencing technologies as requiring "complicated and error-prone image acquisition and analysis steps," often involving moving optical components or device stages, which are expensive and limit signal strength '441 Patent, col. 1:46-59
• The Patented Solution: The invention proposes a bioassay system comprising a dense array of stationary optical detection apparatuses '441 Patent, col. 3:1-4 Each apparatus includes a light detector and a "linker site" positioned in very close proximity to it (e.g., less than 100 micrometers), where a single biomolecule can be affixed '441 Patent, abstract '441 Patent, col. 2:31-40 This close-coupling design allows the detector to capture light from the biomolecule over a large solid angle, enabling sensitive single-molecule detection without the need for complex external optics '441 Patent, col. 2:25-30 '441 Patent, col. 5:26-30
• Technical Importance: This architecture offers a path toward highly parallel, low-cost, single-molecule sequencing, a key goal for realizing the "$1000 genome" paradigm by simplifying hardware and manufacturing '441 Patent, col. 1:60-63

Key Claims at a Glance

• The complaint asserts independent apparatus claim 48 as representative Compl. ¶24
• The essential elements of claim 48 are:
  • An apparatus for identifying a single biomolecule, comprising:
  • a substrate having a light detector;
  • a linker site formed over the light detector, the linker site being treated to affix the biomolecule to the linker site; and
  • an excitation light source formed over the substrate;
  • wherein the linker site is proximate to the light detector and is spaced apart from the light detector by a distance of less than or equal to 100 micrometers.
• The complaint also alleges infringement of at least method claim 16 Compl. ¶54 and states that Plaintiff will assert infringement of one or more claims Compl. ¶23

III. The Accused Instrumentality

Product Identification

The accused products are Defendant's "Sequel" and "Sequel II" nucleic acid sequencing systems Compl. ¶6 Compl. ¶15 Compl. ¶16 Compl. ¶23 The complaint also identifies the consumable "SMRT Cell 1M" and "SMRT Cell 8M" cartridges as necessary components for the systems' operation Compl. ¶16 Compl. ¶30

Functionality and Market Context

• The complaint alleges the Sequel and Sequel II systems are platforms for "single molecule, real-time (SMRT) technology" Compl. ¶28 The systems require the use of SMRT Cells, which are described as nanofabricated consumables containing millions of wells called "zero-mode waveguides (ZMWs)" Compl. ¶31 Compl. ¶33
• Within each ZMW, a single DNA molecule is immobilized via a polymerase enzyme, allowing for real-time observation of base incorporation during sequencing Compl. ¶33 Compl. ¶43 The complaint presents a diagram from the Defendant explaining this process. The diagram depicts a single molecule of DNA immobilized at the bottom of a ZMW for sequencing Compl. ¶33 The complaint alleges these systems provide "higher throughput, more scalability, a reduced footprint and lower sequencing project costs" compared to prior systems Compl. ¶15

IV. Analysis of Infringement Allegations

'441 Patent Infringement Allegations

Claim Element (from Independent Claim 48)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
a substrate having a light detector	The accused Sequel system uses a SMRT Cell 1M, which contains a microchip with a semiconductor substrate that includes one or more CMOS optical sensors that function as light detectors.	¶¶37-40	col. 4:57-59
a linker site formed over the light detector, the linker site being treated to affix the biomolecule to the linker site	The SMRT Cell includes an area within each Zero-Mode Waveguide (ZMW) for affixing a biomolecule. A "DNA template-polymerase complex is immobilized at the bottom of the ZMW," which functions as the linker site.	¶¶41-43	col. 2:35-36
an excitation light source formed over the substrate	The SMRT Cell microchip has a "light-emitting waveguide formed over the semiconductor substrate" that illuminates each ZMW from below to excite the biomolecule.	¶¶45-46; ¶48	col. 6:30-44
wherein the linker site is proximate to the light detector and is spaced apart from the light detector by a distance of less than or equal to 100 micrometers	The SMRT Cell microchip contains a linker site and a light detector that are allegedly separated by a distance of "less than 20 micrometers."	¶52	col. 2:38-40

• Identified Points of Contention:
  • Scope Questions: A potential issue for the court may be whether the accused "zero-mode waveguide (ZMW)" structure constitutes a "linker site" as that term is used in the patent. The complaint alleges the bottom of the ZMW serves as the linker site Compl. ¶43, while the patent's embodiments depict the linker site as an area within a "pinhole" formed in a "blind sheet" '441 Patent, Fig. 2 The analysis may turn on whether the ZMW structure is considered equivalent to the patent's disclosed embodiment.
  • Technical Questions: Claim 48 requires "an excitation light source formed over the substrate." The complaint alleges a "light-emitting waveguide formed over the semiconductor substrate" meets this limitation Compl. ¶46 The patent, however, discloses a specific integrated, multi-layer semiconductor light source (see'441 Patent, Fig. 4). This raises the question of whether the accused waveguide possesses the structural and functional characteristics of the claimed light source as it would be construed by a court.

V. Key Claim Terms for Construction

• The Term: "linker site"

• Context and Importance: The definition of "linker site" is critical, as the infringement theory hinges on equating PacBio's ZMW structure with this claim term. Practitioners may focus on this term because the physical structures disclosed in the patent (a treated area in a pinhole) and used in the accused product (a nanofabricated well) are different.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The claim language itself is functional, defining the term as a "site... treated to affix the biomolecule" '441 Patent, cl. 48 This could support an interpretation covering any location that performs this function, regardless of specific structure.
  • Evidence for a Narrower Interpretation: The specification's primary embodiment shows the linker site (220) as an area formed inside a "pinhole" (235) which is part of a "blind sheet" (230) '441 Patent, Fig. 2 '441 Patent, col. 5:23-25 An argument could be made that the term should be limited to this disclosed configuration, which may differ from the accused ZMW.

• The Term: "an excitation light source formed over the substrate"

• Context and Importance: This term's construction is central to whether the accused product's illumination method infringes. The dispute may center on the degree of physical integration required by the phrase "formed over."

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The plain meaning of "formed over" could suggest any light source constructed in a layer or position above the main detector substrate would meet the limitation.
  • Evidence for a Narrower Interpretation: Figure 4 of the '441 Patent details an embodiment where the excitation source (40) is an integrated structure comprising p-type and n-type semiconductor layers (410, 430) and a light-emitting layer (420) built directly on the device stack '441 Patent, Fig. 4 '441 Patent, col. 6:35-51 This may support an argument that "formed over" requires a specific, directly fabricated, integrated semiconductor structure, not merely a nearby waveguide.

VI. Other Allegations

• Indirect Infringement: The complaint alleges induced infringement, asserting that Defendant provides documentation, including user guides, manuals, and videos, that instruct customers on how to use the accused products in an infringing manner Compl. ¶56 It also alleges contributory infringement on the basis that the accused products and their consumables are specifically designed for this purpose, constitute a material part of the invention, and have no substantial non-infringing uses Compl. ¶57
• Willful Infringement: The willfulness allegation is based on alleged pre-suit knowledge of the '441 Patent. The complaint cites years of licensing discussions between the parties Compl. ¶¶12-14 and alleges that Defendant cited the '441 Patent during the prosecution of its own patent applications Compl. ¶55 Compl. ¶59

VII. Analyst's Conclusion: Key Questions for the Case

• A central question will be one of structural scope: does the accused "zero-mode waveguide" (ZMW) structure in PacBio's SMRT Cells fall within the scope of the claimed "linker site formed over the light detector," particularly in light of the patent's depiction of a linker site within a pinhole in a blind sheet?
• A second key issue will be one of claim construction: does the phrase "an excitation light source formed over the substrate" require the specific, multi-layer integrated semiconductor structure disclosed in the patent's embodiment (Fig. 4), or can it be construed more broadly to cover the alleged waveguide in the accused systems?
• Finally, a threshold issue for the litigation's viability is the impact of the subsequent Inter Partes Review, which cancelled the representative claim 48. The court will need to address whether any remaining patentable claims, which were not the focus of the initial complaint, can support a continued infringement action against the accused products.